IPCA Laboratories Limited (IN:IPCALAB)
:IPCALAB
Want to see IN:IPCALAB full AI Analyst Report?
IPCALAB Stock Chart & Stats
₹1403.75
-₹42.20(-2.43%)
At close: 4:00 PM EST
₹1403.75
-₹42.20(-2.43%)
Day’s Range― - ―
52-Week Range₹1,252.95 - ₹1,679.45
Previous CloseN/A
Volume578.66K
Average Volume (3M)6.78K
Market Cap
₹414.54B
Enterprise Value₹389.19B
Total Cash (Recent Filing)₹12.83B
Total Debt (Recent Filing)₹12.79B
Price to Earnings (P/E)36.2
Beta0.15
Next Earnings
Aug 06, 2026EPS Estimate
10.6Next Dividend Ex-DateN/A
Dividend Yield0.28%
Share Statistics
EPS (TTM)32.78
Shares Outstanding253,659,230
10 Day Avg. Volume6,645
30 Day Avg. Volume6,776
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)5.04
Price to Sales (P/S)4.21
P/FCF Ratio83.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)55.29
Revenue Forecast (FY)₹107.74B
Bulls Say, Bears Say
Bulls Say
Low LeverageA conservative balance sheet with debt-to-equity near 0.10 provides structural resilience: lower interest burden, greater capacity to fund capex or regulatory compliance, and optionality for acquisitions or downturns. This durable financial flexibility supports long-term stability.
Diversified Pharma ModelOperating both finished formulations and APIs across domestic and export markets creates multiple, persistent revenue streams. The mix of branded, generic and B2B supply reduces single-market dependence, supporting steadier earnings and mitigating product- or geography-specific shocks over months.
Sustained ProfitabilityMaintaining mid-40s gross margins and near-double-digit net margins indicates structurally profitable operations and manufacturing scale. Even with compression, these margins support reinvestment and cash generation, underpinning long-term competitive capability in specialty and generic drugs.
Bears Say
Margin CompressionSustained margin erosion suggests worsening mix, cost pressure, or pricing weakness that can structurally reduce returns on capital. If persistent, compressed margins limit reinvestment, dividend capacity and ability to absorb regulatory or R&D spend, weighing on long-term profitability.
Slowing Revenue GrowthTop-line growth slowing to low single digits indicates reduced organic momentum or market saturation in key segments. Over a multi-month horizon, slower revenue expansion constrains earnings leverage, makes margin recovery harder, and increases reliance on efficiency or M&A to sustain earnings growth.
Moderate FCF ConversionSub‑par free cash flow conversion implies working capital needs or capex absorb a sizeable share of earnings. Lower cash conversion reduces capacity for shareholder returns, debt reduction or strategic investments, and increases sensitivity to cyclical cash pressures over the medium term.
IPCA Laboratories Limited News
IPCALAB FAQ
What was IPCA Laboratories Limited’s price range in the past 12 months?
IPCA Laboratories Limited lowest stock price was ₹1252.95 and its highest was ₹1679.45 in the past 12 months.
What is IPCA Laboratories Limited’s market cap?
IPCA Laboratories Limited’s market cap is ₹414.54B.
When is IPCA Laboratories Limited’s upcoming earnings report date?
IPCA Laboratories Limited’s upcoming earnings report date is Aug 06, 2026 which is in 56 days.
How were IPCA Laboratories Limited’s earnings last quarter?
IPCA Laboratories Limited released its earnings results on May 29, 2026. The company reported ₹11.8 earnings per share for the quarter, beating the consensus estimate of ₹10.074 by ₹1.726.
Is IPCA Laboratories Limited overvalued?
According to Wall Street analysts IPCA Laboratories Limited’s price is currently Overvalued.
Does IPCA Laboratories Limited pay dividends?
IPCA Laboratories Limited pays a Semiannually dividend of ₹2 which represents an annual dividend yield of 0.28%. See more information on IPCA Laboratories Limited dividends here
What is IPCA Laboratories Limited’s EPS estimate?
IPCA Laboratories Limited’s EPS estimate is 10.6.
How many shares outstanding does IPCA Laboratories Limited have?
IPCA Laboratories Limited has 253,659,230 shares outstanding.
What happened to IPCA Laboratories Limited’s price movement after its last earnings report?
IPCA Laboratories Limited reported an EPS of ₹11.8 in its last earnings report, beating expectations of ₹10.074. Following the earnings report the stock price went down -3.753%.
Which hedge fund is a major shareholder of IPCA Laboratories Limited?
Currently, no hedge funds are holding shares in IN:IPCALAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IPCA Laboratories Limited
Ipca Laboratories Limited is a pharmaceutical company that manufactures and distributes a comprehensive range of finished drug products (formulations) and essential raw materials, known as Active Pharmaceutical Ingredients (APIs). Its API portfolio supports treatments for conditions such as hypertension, malaria, parasitic infections, and also includes diuretics and disease-modifying anti-rheumatic drugs (DMARDs). The company provides an extensive selection of generic and branded formulations across numerous therapeutic segments. These encompass cardiovascular health, diabetes management, neurological disorders, gastroenterology, and dermatology. Furthermore, Ipca's product lines address oncology, rheumatology, respiratory conditions, ophthalmology, urology, mental health, infectious diseases, pain management, allergies, nutritional support, and various other specialized medical requirements. Primarily operating in India, Ipca Laboratories also boasts a significant international footprint, exporting its products to approximately 100 countries worldwide. The company, which has its headquarters in Mumbai, India, was established in 1949.
Technical Analysis
Ajanta Pharma Limited
―
Emcure Pharmaceuticals Limited
―
JB Chemicals & Pharmaceuticals Ltd.
―
Neuland Laboratories Ltd.
―
Wockhardt Limited
―